Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin

Tissue Engineering - Part A

Volumn 21, Issue 3-4, 2015, Pages 767-781

  Bassi, Giulio ^a   Guilloton, Fabien ^b   Menard, Cedric ^c   Di Trapani, Mariano ^a   Deschaseaux, Frederic ^b   Sensebé, Luc ^b   Schrezenmeier, Hubert ^d   Giordano, Rosaria ^e   Bourin, Philippe ^b,f   Dominici, Massimo ^g   Tarte, Karin ^c   Krampera, Mauro ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d UNIVERSITY OF ULM   (Germany)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f CSA21   (France)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CHEMICAL ACTIVATION; FLOWCHARTING; HYDROXYAPATITE; MACHINERY; SCAFFOLDS (BIOLOGY); T-CELLS;

BONE MORPHOGENETIC PROTEIN-4; BONE TISSUE ENGINEERING; INFLAMMATORY CYTOKINES; LONG-TERM CULTURE; MESENCHYMAL STROMAL CELLS; SHORT-TERM CULTURES; THERAPEUTIC ACTIVITY; TRI-CALCIUM PHOSPHATES;

CELL CULTURE;

B7 ANTIGEN; BIOCERAMICS; BONE MORPHOGENETIC PROTEIN 4; CALCIUM PHOSPHATE; CD86 ANTIGEN; CYCLOOXYGENASE 2; DEXAMETHASONE; GAMMA INTERFERON; HLA DR ANTIGEN; HYDROXYAPATITE; INDOLEAMINE 2,3 DIOXYGENASE; OSTEOCALCIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; BONE PROSTHESIS; CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS; IMMUNOLOGIC FACTOR;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BIOCOMPATIBILITY; BONE DEFECT; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MINERALIZATION; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CELLS BY BODY ANATOMY; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL CULTURE; T LYMPHOCYTE; TISSUE ENGINEERING; UPREGULATION; BONE PROSTHESIS; CELL CULTURE; CERAMICS; CHEMISTRY; CYTOLOGY; DEVICE FAILURE ANALYSIS; DRUG EFFECTS; EQUIPMENT DESIGN; IMMUNOLOGY; MATERIALS TESTING; MESENCHYMAL STROMA CELL; PHARMACOLOGY; TISSUE SCAFFOLD;

BONE SUBSTITUTES; CALCIUM PHOSPHATES; CELL DIFFERENTIATION; CELLS, CULTURED; CERAMICS; DURAPATITE; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MATERIALS TESTING; MESENCHYMAL STROMAL CELLS; TISSUE SCAFFOLDS;

EID: 84923273831     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2014.0269     Document Type: Article

References (57)

1. Okamoto, K., and Takayanagi, H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther 13, 219, 2011.
2. Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7, 292, 2007.
3. Schmidt-Bleek, K., Schell, H., Schulz, N., Hoff, P., Perka, C., Buttgereit, F., Volk, H-D., Lienau, J., and Duda, G.N. Inflammatory phase of bone healing initiates the regenerative healing cascade. Cell Tissue Res 347, 567, 2012.
4. Claes, L., Recknagel, S., and Ignatius, A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol 8, 133, 2012.
5. Audigé, L., Griffin, D., Bhandari, M., Kellam, J., and Rüedi, T.P. Path analysis of factors for delayed healing and nonunion in 416 operatively treated tibial shaft fractures. Clin Orthop Relat Res 438, 221, 2005.
6. Dimitriou, R., Jones, E., McGonagle, D., and Giannoudis P.V. Bone regeneration: current concepts and future directions. BMC Med 9, 66, 2011.
7. Lin, C.-L., Fang, C.-K., Chiu, F.-Y., Chen, C.-M., and Chen, T.-H. Revision with dynamic compression plate and cancellous bone graft for aseptic nonunion after surgical treatment of humeral shaft fracture. J Trauma 67, 1393, 2009.
8. Kurz, L.T., Garfin, S.R., and Booth, R.E. Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine 14, 1324, 1989.
9. Myeroff, C., and Archdeacon, M. Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am 93, 2227, 2011.
10. Bueno, E.M., and Glowacki, J. Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol 5, 685, 2009.
11. Dupont, K.M., Boerckel, J.D., Stevens, H.Y., Diab, T., Kolambkar, Y.M., Takahata, M., Schwarz, E.M., and Guldberg, R.E. Synthetic scaffold coating with adenoassociated virus encoding BMP2 to promote endogenous bone repair. Cell Tissue Res 347, 575, 2012.
12. Cordonnier, T., Langonné, A., Sohier, J., Layrolle, P., Rosset, P., Sensébé, L., and Deschaseaux, F. Consistent osteoblastic differentiation of human mesenchymal stem cells with bone morphogenetic protein 4 and low serum. Tissue Eng Part C Methods 17, 249, 2010.
13. Uccelli, A., Moretta, L., and Pistoia, V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 8, 726, 2008.
14. Gotherstrom, C., Ringden, O., Tammik, C., Zetterberg, E., Westgren, M., and Le Blanc, K. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 190, 239, 2004.
15. Ding, S.J., Shie, M.Y., Hoshiba, T., Kawazoe, N., Chen, G., and Chang, H.C. Osteogenic differentiation and immune response of human bone-marrow-derived mesenchymal stem cells on injectable calcium-silicate-based bone grafts. Tissue Eng Part A 16, 2343, 2010.
16. Wang, L., Lu, X.F., Lu, Y.R., Liu, J., Gao, K., Zeng, Y.Z., Li, S.F., Li, Y.P., Cheng, J.Q., Tan, W.D., and Wan, L. Immunogenicity and immune modulation of osteogenic differentiated mesenchymal stem cells from Banna minipig inbred line. Transplant Proc 38, 2267, 2006.
17. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., and Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31, 890, 2003.
18. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M.E., Remberger, M., Dini, G., Egeler, R.M., Bacigalupo, A., Fibbe, W., and Ringdén, O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study. Lancet 371, 1579, 2008.
19. Connick, P., Kolappan, M., Crawley, C., Webber, D.J., Patani, R., Michell, A.W., Du, M.-Q., Luan, S.-L., Altmann, D.R., Thompson, A.J., Compston, A., Scott, M.A., Miller, D.H., and Chandran, S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-ofconcept study. Lancet Neurol 11, 150, 2012.
20. Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., Gao, X., Pileggi, A., and Ricordi, C. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307, 1169, 2012.
21. Marini, J.C., and Forlino, A. Replenishing cartilage from endogenous stem cells. N Engl J Med 366, 2522, 2012.
22. Vacanti, C.A., Bonassar, L.J., Vacanti, M.P., and Shufflebarger, J. Replacement of an avulsed phalanx with tissue-engineered bone. N Engl J Med 344, 1511, 2001.
23. Xu, J., Wang, W., Ludeman, M., Cheng, K., Hayami, T., Lotz, J.C., and Kapila, S. Chondrogenic differentiation of human mesenchymal stem cells in three-dimensional alginate gels. Tissue Eng Part A 14, 667, 2008.
24. Cordonnier, T., Layrolle, P., Gaillard, J., Langonné, A., Sensebé, L., Rosset, P., and Sohier, J. 3D environment on human mesenchymal stem cells differentiation for bone tissue engineering. J Mater Sci Mater Med 21, 981, 2010.
25. Roch, T., Krüger, A., Kratz, K., Ma, N., Jung, F., and Lendlein, A. Immunological evaluation of polystyrene and poly(ether imide) cell culture inserts with different roughness. Clin Hemorheol Microcirc 52, 375, 2012.
26. Fellah, B.H., Delorme, B., Sohier, J., Magne, D., Hardouin, P., and Layrolle, P. Macrophage and osteoblast responses to biphasic calcium phosphate microparticles. J Biomed Mater Res A 93, 1588, 2010.
27. Krampera, M., Galipeau, J., Shi, Y., Tarte, T., and Sensebe, L. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054, 2013.
28. Akiyama, K., Chen, C., Wang, D., Xu, X., Qu, C., Yamaza, T., Cai, T., Chen, W., Sun, L., and Shi, S. Mesenchymalstem-cell-induced immunoregulation involves FAS-ligand-/ FAS-mediated T cell apoptosis. Cell Stem Cell 10, 544, 2012.
29. Benvenuto, F., Ferrari, S., Gerdoni, E., Gualandi, F., Frassoni, F., Pistoia, V., Mancardi, G., and Uccelli, A. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 27, 1753, 2007.
30. Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P.D., Matteucci, P., Grisanti, S., and Gianni, A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838, 2002.
31. Menard, C., Pacelli, L., Bassi, G., Dulong, J., Bifari, F., Bezier, I., Zanoncello, J., Ricciardi, M., Latour, M., Bourin, P., Schrezenmeier, H., Sensebé, L., Tarte, K., and Krampera, M. Clinical-grade mesenchymal stromal cells produced under various GMP processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22, 1789, 2013.
32. Fekete, N., Gadelorge, M., Furst, D., Maurer, C., Dausend, J., Fleury-Cappellesso, S., Mailander, V., Lotfi, R., Ignatius, A., Sensebe, L., Bourin, P., Schrezenmeier, H., and Rojewski, M.T. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14, 540, 2012.
33. Khan, Y., Yaszemski, M.J., Mikos, A.G., and Laurencin, C.T. Tissue engineering of bone: material and matrix considerations. J Bone Joint Surg Am 90, 36, 2008.
34. Petite, H., Viateau, V., Bensaïd, W., Meunier, A., De Pollak, C., Bourguignon, M., Oudina, K., Sedel, L., and Guillemin, G. Tissue-engineered bone regeneration. Nat Biotechnol 18, 959, 2000.
35. Dupont, K.M., Sharma, K., Stevens, H.Y., Boerckel, J.D., Garcia, A.J., and Guldberg, R.E. Regenerative medicine special feature: human stem cell delivery for treatment of large segmental bone defects. PNAS 107, 3305, 2010.
36. Gnecchi, M., He, H., Liang, O.D., Melo, L.G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R.E., Ingwall, J.S., and Dzau, V.J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11, 367, 2011.
37. Atkins, G.J., Welldon, K.J., Holding, C.A., Haynes, D.R., Howie, D.W., and Findlay, D.M. The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30, 3672, 2009.
38. Lavenus, S., Pilet, P., Guicheux, J., Weiss, P., Louarn, G., and Layrolle, P. Behaviour of mesenchymal stem cells, fibroblasts and osteoblasts on smooth surfaces. Acta Biomater 30, 1525, 2011.
39. Kern, S., Eichler, H., Stoeve, J., Klüter, H., and Bieback, K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24, 1294, 2006.
40. Zhang, Z.-Y., Teoh, S.-H., Hui, J.H.P., Fisk, N.M., Choolani, M., and Chan, J.K.Y. The potential of human fetal mesenchymal stem cells for off-The-shelf bone tissue engineering application. Biomaterials 33, 2656, 2012.
41. Al-Nbaheen, M., Vishnubalaji, R., Ali, D., Bouslimi, A., Al-Jassir, F., Megges, M., Prigione, A., Adjaye, J., Kassem, M., and Aldahmash, A. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev 9, 32, 2013.
42. Lee, J.-S., Lee, J.-M., and Im, G.-I. Electroporation-mediated transfer of Runx2 and Osterix genes to enhance osteogenesis of adipose stem cells. Biomaterials 32, 760, 2011.
43. Pinheiro, C.H., de Queiroz, J.C., Guimaraes-Ferreira, L., Vitzel, K.F., Nachbar, R.T., de Sousa, L.G., de Souza-Jr, A.L., Nunes, M.T., and Curi, R. Local injections of adipose-derived mesenchymal stem cells modulate inflammation and increase angiogenesis ameliorating the dystrophic phenotype in dystrophin-deficient skeletal muscle. Stem Cell Rev 8, 363, 2012.
44. Arinzeh, T.L., Tran, T., Mcalary, J., and Daculsi, G. A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation. Biomaterials 26, 3631, 2005.
45. Habibovic, P., Yuan, H., van der Valk, C.M., Meijer, G., Van Blitterswijk, C.A., and de Groot, K. 3D microenvironment as essential element for osteoinduction by biomaterials. Biomaterials 26, 3565, 2005.
46. Jégoux, F., Goyenvalle, E., Cognet, R., Malard, O., Moreau, F., Daculsi, G., and Aguado, E. Mandibular segmental defect regenerated with macroporous biphasic calcium phosphate, collagen membrane, and bone marrow graft in dogs. Arch Otolaryngol Head Neck Surg 136, 971, 2010.
47. Eyckmans, J., Roberts, S.J., Bolander, J., Schrooten, J., Chen, C.S., and Luyten, F.P. Mapping calcium phosphate activated gene networks as a strategy for targeted osteoinduction of human progenitors. Biomaterials 34, 4612, 2013.
48. Chai, Y.C., Roberts, S.J., Desmet, E., Kerckhofs, G., van Gastel, N., Geris, L., Carmeliet, G., Schrooten, J., and Luyten, F.P. Mechanisms of ectopic bone formation by human osteoprogenitor cells on CaP biomaterial carriers. Biomaterials 33, 3127, 2012.
49. Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A., and Ji, W. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27, 1954, 2009.
50. Lang, J., Kelly, M., Freed, B.M., McCarter, M.D., Kedl, R.M., Torres, R.M., and Pelanda, R. Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation. J Immunol 190, 2090, 2013.
51. Skjødt, H., Møller, T., and Freiesleben, S.F. Human osteoblast-like cells expressing MHC class II determinants stimulate allogeneic and autologous peripheral blood mononuclear cells and function as antigen-presenting cells. Immunology 68, 416, 1989.
52. Ward, W.G., Gautreaux, M.D., Lippert, D.C., and Boles, C. HLA sensitization and allograft bone graft incorporation. Clin Orthop Relat Res 466, 1837, 2008.
53. Lau, K.H., Kothari, V., Das, A., Zhang, X.B., and Baylink, D.J. Cellular and molecular mechanisms of accelerated fracture healing by COX2 gene therapy: studies in a mouse model of multiple fractures. Bone 53, 369, 2013.
54. Martin, P., and Leibovich, S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 15, 599, 2005.
55. Huang, H., Zhao, N., Xu, X., Xu, Y., Li, S., Zhang, J., and Yang, P. Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells. Cell Prolif 44, 420, 2011.
56. Liu, Y., Wang, L., Kikuiri, T., Akiyama, K., Chen, C., Xu, X., Yang, R., Chen, W., Wang, S., and Shi, S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-g and TNF-A. Nat Med 17, 1594, 2011.
57. Gerstenfeld, L.C., Cho, T.J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T., and Einhorn, T.A. Impaired fracture healing in the absence of TNF-Alpha signaling: the role of TNF-Alpha in endochondral cartilage resorption. J Bone Miner Res 18, 1584, 2003.